Biocartis Group NV (BCART) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biocartis Group NV (BCART) has a cash flow conversion efficiency ratio of 0.542x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-29.29 Million ≈ $-34.24 Million USD) by net assets (€-53.99 Million ≈ $-63.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Biocartis Group NV for the company's overall valuation and market capitalisation.
Biocartis Group NV - Cash Flow Conversion Efficiency Trend (2012–2022)
This chart illustrates how Biocartis Group NV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biocartis Group NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biocartis Group NV ranked by their cash flow conversion efficiency. See Biocartis Group NV debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ELUON Corporation
KQ:065440
|
0.115x |
|
Ribbon Acquisition Corp Class A Ordinary Shares
NASDAQ:RIBB
|
0.000x |
|
SAF Tehnika A/S
F:VTZ
|
0.104x |
|
Inderes Oyj
HE:INDERES
|
0.074x |
|
SunCar Technology Group Inc.
NASDAQ:SDA
|
0.185x |
|
Nova EYE Medical Ltd
AU:EYE
|
-0.059x |
|
Scienjoy Holding Corp
NASDAQ:SJ
|
0.008x |
|
Optrontec Inc
KQ:082210
|
0.142x |
Annual Cash Flow Conversion Efficiency for Biocartis Group NV (2012–2022)
The table below shows the annual cash flow conversion efficiency of Biocartis Group NV from 2012 to 2022. View latest Biocartis Group NV stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | €-30.28 Million ≈ $-35.41 Million |
€-44.85 Million ≈ $-52.44 Million |
1.481x | -23.60% |
| 2021-12-31 | €-33.90 Million ≈ $-39.63 Million |
€-65.72 Million ≈ $-76.83 Million |
1.939x | +281.81% |
| 2020-12-31 | €36.82 Million ≈ $43.05 Million |
€-39.27 Million ≈ $-45.91 Million |
-1.066x | -66.04% |
| 2019-12-31 | €84.48 Million ≈ $98.76 Million |
€-54.25 Million ≈ $-63.43 Million |
-0.642x | -33.59% |
| 2018-12-31 | €87.35 Million ≈ $102.12 Million |
€-41.99 Million ≈ $-49.09 Million |
-0.481x | -53.54% |
| 2017-12-31 | €132.24 Million ≈ $154.60 Million |
€-41.41 Million ≈ $-48.41 Million |
-0.313x | +43.10% |
| 2016-12-31 | €96.89 Million ≈ $113.27 Million |
€-53.31 Million ≈ $-62.33 Million |
-0.550x | -170.72% |
| 2015-12-31 | €114.92 Million ≈ $134.35 Million |
€-23.36 Million ≈ $-27.31 Million |
-0.203x | +88.51% |
| 2014-12-31 | €20.28 Million ≈ $23.71 Million |
€-35.88 Million ≈ $-41.95 Million |
-1.769x | -37.31% |
| 2013-12-31 | €31.95 Million ≈ $37.36 Million |
€-41.18 Million ≈ $-48.14 Million |
-1.289x | -14.93% |
| 2012-12-31 | €36.80 Million ≈ $43.02 Million |
€-41.26 Million ≈ $-48.24 Million |
-1.121x | -- |
About Biocartis Group NV
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progres… Read more